<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119742</url>
  </required_header>
  <id_info>
    <org_study_id>BTNF-0909</org_study_id>
    <nct_id>NCT01119742</nct_id>
  </id_info>
  <brief_title>Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis</brief_title>
  <acronym>BNF-0909</acronym>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams to Lotrimin UltraÂ® Cream in Patients With Interdigital Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate comparable safety and efficacy of Taro Pharmaceuticals, Inc butenafine
      hydrochloride cream 1% test product and Lotrimin Ultra cream (reference listed drug) in the
      treatment of interdigital tinea pedis, and to show the superiority of the active treatments
      over that of the placebo (vehicle).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient number of baseline eligible patient
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic Cure</measure>
    <time_frame>42 Days</time_frame>
    <description>Patients with clinical cure and mycologic cure are considered therapeutic cures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure</measure>
    <time_frame>42 days</time_frame>
    <description>Patient will be considered a &quot;clincal cure&quot; if the score for erythema is equal or less than 2 and the total score for all of the other seven signs and symptoms is less than 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycologic Cure</measure>
    <time_frame>42 Days</time_frame>
    <description>Patient will be considered a &quot;mycological cure&quot; if the results of both the potassium hydroxide (KOH) and the fungal culture are negative.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">428</enrollment>
  <condition>Interdigital Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Butenafine Hydrochloride 1% A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Butenafine Hydrochloride 1% B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Butenafine Hydrochloride 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butenafine Hydrochloride 1%</intervention_name>
    <description>Twice daily application for 7 days</description>
    <arm_group_label>Butenafine Hydrochloride 1% A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butenafine Hydrochloride 1% B</intervention_name>
    <description>Twice daily application for 7 days</description>
    <arm_group_label>Butenafine Hydrochloride 1% B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butenafine Hydrochloride 1%</intervention_name>
    <description>Twice daily application for 7 days</description>
    <arm_group_label>Butenafine Hydrochloride 1%</arm_group_label>
    <other_name>Lotrimin Ultra Cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle A</intervention_name>
    <description>Twice daily application for 7 days</description>
    <arm_group_label>Vehicle A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle B</intervention_name>
    <description>Twice daily application for 7 days</description>
    <arm_group_label>Vehicle B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant, non lactating females 18 years of age or older.

          2. Signed informed consent form, which meets all criteria of current FDA regulations and
             the requirements of the India regulatory authorities.

          3. If female and of child bearing potential, have a negative urine pregnancy test at the
             baseline visit,

          4. A total score of at least six (6) for the following eight (8) clinical signs and
             symptoms of interdigital tinea pedis: fissuring, erythema, maceration, vesiculation,
             desquamation/scaling, exudation, pruritus, burning/stinging. In addition the most
             infected area must have a minimum score of at least 2 for erythema and a minimum score
             of at least 2 for either pruritus or desquamation/scaling

          5. A confirmed clinical diagnosis of interdigital tinea pedis.

          6. The presence of tinea pedis infection, confirmed by the observation of segmented
             fungal hyphae during a microscopic KOH wet mount examination (potassium hydroxide
             mount preparation).

          7. Identification of an appropriate dermatophyte by culture sent to the central
             laboratory. The appropriate dermatophytes are Trichophyton rubrum, Trichophyton
             mentagrophytes or Epidermophyton floccosum.

        Exclusion Criteria:

          1. Use of any of the following within the indicated timeline:

               -  Oral or injectable steroids within four weeks of the study start.

               -  Any oral anti-fungals within 4 weeks of the study start.

               -  Use of topical corticosteroids or any other topical antipruritics on the feet
                  within 72 hours of the study start.

               -  Any prescription or OTC topical antifungal on the feet within two weeks prior to
                  study entry.

               -  Use of any antihistamines within 72 hours of the study start.

          2. Any known hypersensitivity to butenafine or other antifungal agents.

          3. Evidence of any concurrent dermatophytic infection of toe nails (onychomycosis) or
             other dermatological condition of the foot that may interfere with the Investigators
             evaluation of tinea pedis.

          4. Patients with recurrent tinea pedis (more than 3 infections in the past 12 months) who
             have been unresponsive to previous antifungal therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2010</study_first_posted>
  <last_update_submitted>May 5, 2014</last_update_submitted>
  <last_update_submitted_qc>May 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinea Pedis</keyword>
  <keyword>Interdigital</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Butenafine</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

